US 11118186
Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
granted A61KA61K31/136A61K31/137
Quick answer
US patent 11118186 (Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer) held by The Board of Regents of the University of Texas System expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/136, A61K31/137, A61K31/337, A61K31/52